NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for HT-1080 Cells (Fibrosarcoma Cells, CCL-121)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
- Download HT1080 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for HT1080 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 80% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems HT-1080 Transfection Protocol: [PDF]
Download MSDS: [PDF]
HT-1080 Cell Line:
Fibrosarcoma is a malignant tumor originating from fibrous connective tissue that mostly affects men in their 30s and 40s and involves immature proliferating fibroblasts. The HT-1080 cell line was originally established in 1972 from the tumorigenic connective tissue of a 35-year-old Caucasian male patient with fibrosarcoma. These cells exhibit an epithelial morphology and contain an activated N-ras oncogene. HT-1080 cells are susceptible to a variety of viruses, including polio, RD-114 feline virus, feline leukemia virus, and vesicular stomatitis virus. These cells are used for research related to cancer of connective tissues. A life science company Altogen Biosystems manufactures in vitro transfection kits for a vast array of cell lines, including the two-component lipid-based advanced formulation HT-1080 transfection reagent kit for human fibrosarcoma cells that yields high transfection efficiency of siRNA delivery.
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the HT-1080 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPDH in HT-1080 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into HT-1080 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, electroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6825)
- 1.5 ml (Catalog #6826)
- 1.5 ml CRISPR (Catalog #2156)
- 8.0 ml (Catalog #6827)